Teva Pharmaceuticals is discontinuing its Phase 2 clinical trial of emrusolmin, an experimental oral drug being investigated for multiple system atrophy (MSA), a rare neurodegenerative disorder. The decision follows an interim analysis in which an independent data monitoring committee concluded that the study had a low probability of meeting its primary efficacy endpoint if it continued. Teva reported that the assessment identified no safety concerns. The company will analyse the available data before making a final decision about the drug’s broader development programme.
Interim Analysis Prompts Trial Discontinuation
The study, known as TOPAS-MSA, began in 2024 and was designed to enrol approximately 350 patients. It was evaluating the efficacy and safety of emrusolmin in adults with MSA, a condition that can cause people to lose coordination and balance or experience slowed movement and stiffness.
The trial was expected to conclude in 2027. However, a planned interim analysis led the independent data monitoring committee to recommend discontinuing the study after assessing the likelihood of achieving its primary objective.
Teva said the committee’s assessment indicated a “low probability of the study meeting its primary efficacy endpoint if continued.” The company clarified that this was a predictive interim assessment rather than the trial’s final efficacy analysis.
The study’s primary endpoint was to measure changes from baseline in patients’ symptom scores over 48 weeks. Emrusolmin was designed to target alpha-synuclein, a key disease mechanism in MSA. The trial was intended to evaluate whether the experimental treatment could demonstrate efficacy while also assessing its safety.
Although the study is being discontinued, Teva reported that the interim analysis did not identify any safety concerns.
Teva Plans Comprehensive Data Review
The discontinuation does not represent a final decision on the wider emrusolmin programme. Teva plans to review the TOPAS-MSA findings comprehensively before determining the next steps for the drug’s development. The company also intends to share the study’s findings with the scientific community after completing its analysis.
Eric Hughes, M.D., Ph.D., Teva’s chief medical officer, acknowledged the disappointing outcome while emphasising the company’s intention to examine the evidence collected during the trial.
“While we are disappointed by the outcome of this interim analysis for the Phase 2 study, we remain deeply committed to learning everything we can from these data,” Hughes said.
He also expressed gratitude to the patients, families, investigators and study teams who contributed to the research. Hughes said the scientific findings could deepen understanding of MSA and help the company determine a possible direction for emrusolmin.
The drug is being developed in partnership with Germany-based biotechnology company MODAG GmbH.
Emrusolmin’s Place in Teva’s Drug Development Strategy
Emrusolmin was among the medicines supporting Teva’s efforts to expand its innovative drug development activities beyond its traditional generics business. When the company launched the phase 2 trial in 2024, the programme was a key component of that strategy.
Other medicines in Teva’s innovative portfolio include duvakitug, an anti-TL1A antibody, and a long-acting injectable formulation of olanzapine, an antipsychotic drug. Both continue to feature in the company’s innovative medicines portfolio, while emrusolmin was not mentioned in Teva’s most recent portfolio update cited in the supplied material.
Leerink Partners analyst Daniel Clark said expectations for the emrusolmin trial had been measured because of limited clinical evidence and the history of unsuccessful candidates targeting alpha-synuclein aggregation in MSA.
Teva will complete its review before determining the future direction of emrusolmin. The company has confirmed that the decision applies to the TOPAS-MSA trial and does not, by itself, end development of the drug.
Teva Discontinues Phase 2 Emrusolmin Trial
Teva Pharmaceuticals has announced the discontinuation of its Phase 2 TOPAS-MSA clinical trial evaluating Emrusolmin in adults with multiple system atrophy (MSA), following an interim analysis that indicated a low probability of achieving the study’s primary efficacy endpoint.
The announcement, made on November 2, 2026, represents a setback for Teva’s neuroscience research program and the development of potential treatments for this rare and progressive neurological disorder.
The decision followed a recommendation from an independent data monitoring committee (IDMC), which reviewed interim clinical data and concluded that the study met its predefined futility criteria. According to Teva, continuing the trial was unlikely to produce the results needed to meet its primary objective.
Clinical setbacks can influence research priorities, investment decisions, and future development strategies. However, the data generated through unsuccessful or discontinued trials can still provide valuable scientific insights.
Teva’s planned review will be important in determining whether any findings from the discontinued study can support further research into Emrusolmin.
What Happens Next for Emrusolmin?
The next major step for Emrusolmin will be Teva’s comprehensive evaluation of the available clinical evidence.
Researchers will need to examine the TOPAS-MSA findings alongside open-label extension data before determining whether additional development opportunities exist.
The company has not provided a definitive timeline for announcing its broader development decision.
For patients, researchers, and the pharmaceutical industry, the outcome highlights the continuing challenges of developing disease-modifying treatments for rare neurodegenerative disorders.
Despite the disappointing interim results, the scientific information collected during the Emrusolmin program may contribute to a better understanding of alpha-synuclein biology and future therapeutic approaches for multiple system atrophy.
